iBio Inc.

iBio Technology

The iBio Technology platform is a proprietary gene expression technology that causes non-transgenic plants to rapidly produce high levels of target proteins.

iBio Technology

Advantages of iBio Technology

Flexible

Flexible

Able to express complex proteins that have failed in other systems

Rapid

Rapid

No need to identify high-producing cell clones. From gene sequence to protein production in three weeks

Sustainable

Sustainable

Non-GMO plants are the bioreactors

Economical

Economical

Reduced capital investment and reduced COGs

Safer

Safer

No animal products and their pathogens

Multi-use facility

Multi-use facility

Manufacture in multiple campaigns in a single facility

How it works

Making Biopharmaceuticals From Plants

The iBio Technology platform offers significant advantages over earlier plant-based methods that rely on transgenic plants of plant cel cultures.

How it works
1
iBio scientists engineer vectors containing the target sequence within a viral replicon
2
The vector is transferred to a bacterium that efficiently introduces target DNA to the plant cell nucleus
3
The viral replicon directs the production of large amounts of target-specific messenger RNA in plant cells, which is translated into protein by the plant’s own machinery for several days
4
The target protein is extracted and purified from the plant, and subsequently used as a vaccine antigen or biotherapeutic drug

Applications

iBio Technology has been used to produce vaccines and biotherapeutic proteins across a wide range of protein classes. Along with the technology, these products are available for license and further development. We are currently focusing our internal efforts on iBio CFB03, a first-in-class treatment for fibrotic diseases including systemic scleroderma and idiopathic pulmonary fibrosis. iBio CFB03 is currently in preclinical development, where it has shown the ability to reverse established fibrotic disease in widely used animal models of scleroderma and pulmonary fibrosis. In addition to iBio CFB03, we can extend commercial license for product candidates in influenza and flavivirus vaccines, hookworm and malaria vaccines, enzyme replacement therapies, monoclonal antibodies, and antibody-therapeutic payload combinations.

Systemic scleroderma, Idiopathic pulmonary fibrosis (IPF), and other fibrotic diseases

Partnership Projects

iBio's business strategy is to broadly participate in the markets that the iBio Technology platform addresses.
Current partner projects include:

iBio Technology Partner

Market

Product

Status

Oswaldo Cruz Foundation
Oswaldo Cruz Foundation
Viral Disease Vaccines
Yellow Fever
Animal efficacy demonstrated
DoD (DARPA)
DoD (DARPA)
Viral Disease Vaccines
H5N1 and H1N1 Influenza
Completed Phase 1 clinical trials
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
Viral Disease Vaccines
H5N1 and H1N1 Influenza
Completed Phase 1 clinical trials
GE Healthcare
GE Healthcare
Facility Design
Facility Design
Conceptual & Basic Design Completed
National Institutes of Health
National Institutes of Health
Bacterial Disease Infection
Anthrax
IND submitted
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation
Parasitic Pathogen Vaccine
Malaria
Phase 1 underway
Sabin Institute
Sabin Institute
Parasite Vaccines
Hookworm
Phase 1 underway
Medical University of South Carolina
Fibrotic Disease
iBio CFB03
Preclinical

Learn More About Partnerships

iBio is establishing partnerships through iBio Technology platform licensing arrangements and product collaborations.

Interested in Becoming a Partner?